You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
